Literature DB >> 7751261

Case study: antimanic effectiveness of dextroamphetamine in a brain-injured adolescent.

J E Max1, L Richards, G Hamdan-Allen.   

Abstract

A relatively enduring and counterintuitive antimanic response to dextroamphetamine in a brain-injured adolescent who had failed trials involving divalproex, lithium, haloperidol, and carbamazepine is described. This finding combined with data from previous reports of antimanic effects of test doses of stimulants imply that such a pharmacological probe may prove relevant for the prediction of treatment response of mania to dextroamphetamine and perhaps for subclassification of bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751261

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  4 in total

Review 1.  Use of Stimulants in Bipolar Disorder.

Authors:  Giulio Perugi; Giulia Vannucchi; Fulvio Bedani; Ettore Favaretto
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

Review 2.  Neuropsychiatry of pediatric traumatic brain injury.

Authors:  Jeffrey E Max
Journal:  Psychiatr Clin North Am       Date:  2014-01-14

3.  [Manic behavior as an autoregulatory attempt to stabilize vigilance].

Authors:  U Hegerl; S Olbrich; P Schönknecht; C Sander
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

4.  Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate.

Authors:  Michael Kluge; Ulrich Hegerl; Christian Sander; Jens Dietzel; Roland Mergl; Istvan Bitter; Koen Demyttenaere; Ricardo Gusmão; Ana Gonzalez-Pinto; Victor Perez-Sola; Eduard Vieta; Georg Juckel; Ulrich S Zimmermann; Michael Bauer; Pascal Sienaert; Sónia Quintão; Marc-Andreas Edel; Csilla Bolyos; Jose Luis Ayuso-Mateos; Pilar López-García
Journal:  BMC Psychiatry       Date:  2013-02-27       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.